FNA Stock Overview
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Paragon 28, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.97 |
| 52 Week High | US$19.72 |
| 52 Week Low | US$7.95 |
| Beta | 1.01 |
| 1 Month Change | -12.49% |
| 3 Month Change | -26.95% |
| 1 Year Change | -51.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.06% |
Recent News & Updates
Recent updates
Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA)
Apr 17
Paragon 28, Inc. (NYSE:FNA) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 03After Leaping 29% Paragon 28, Inc. (NYSE:FNA) Shares Are Not Flying Under The Radar
Nov 28Paragon 28 announces public offering of 6.5M shares
Jan 25Paragon 28 guides Q4 and FY22 revenue outlook above consensus
Jan 10Paragon 28 GAAP EPS of -$0.13 misses by $0.01, revenue of $46M beats by $3.52M
Nov 10US$25.00: That's What Analysts Think Paragon 28, Inc. (NYSE:FNA) Is Worth After Its Latest Results
May 12Shareholder Returns
| FNA | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.0% | 1.6% | 1.0% |
| 1Y | -51.4% | -1.4% | 21.9% |
Return vs Industry: FNA underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: FNA underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| FNA volatility | |
|---|---|
| FNA Average Weekly Movement | 10.1% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FNA's share price has been volatile over the past 3 months.
Volatility Over Time: FNA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 574 | Albert DaCosta | paragon28.com |
Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis.
Paragon 28, Inc. Fundamentals Summary
| FNA fundamental statistics | |
|---|---|
| Market cap | US$743.67m |
| Earnings (TTM) | -US$47.84m |
| Revenue (TTM) | US$216.39m |
3.4x
P/S Ratio-15.5x
P/E RatioIs FNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNA income statement (TTM) | |
|---|---|
| Revenue | US$216.39m |
| Cost of Revenue | US$43.60m |
| Gross Profit | US$172.79m |
| Other Expenses | US$220.63m |
| Earnings | -US$47.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 79.85% |
| Net Profit Margin | -22.11% |
| Debt/Equity Ratio | 62.1% |
How did FNA perform over the long term?
See historical performance and comparison